Skip to content

Physical Exercise as a Sustainability Tool in Men With Dysmetabolic Hypogonadism

Physical Exercise as a Sustainability Tool in Men Affected With Metabolic Syndrome-related Late-onset Central Hypogonadism: Role of Endocrine-metabolic and Neurovegetative Outcomes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06094036
Acronym
ExLOH
Enrollment
72
Registered
2023-10-23
Start date
2023-01-11
Completion date
2024-12-31
Last updated
2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Imbalance, Hypogonadism, Male, Life Style, Healthy, Metabolic Syndrome, Physical Inactivity

Brief summary

Aim of this project is to delineate sustainable physical exercise programs and to assess the effects of such programs mainly on endocrine-metabolic and neurovegetative outcomes in a cohort of men with metabolic syndrome-related late-onset central hypogonadism. Participants will undergo a personalised exercise program. After 6 months they will be subdivided into two groups, according to the weekly physical activity volume actually performed (above or below 600 MET·minutes/week). Changes in endocrine-metabolic and neurovegetative outcomes will be compared between the two groups.

Interventions

BEHAVIORALStructured and personalized program of physical exercise

In line with the most recent guidelines, exercise prescription will require the clear definition of modality, intensity, frequency, duration and progression of exercise, tailored on patient's clinical conditions and goals. This intervention will be accompanied by a nutrition program aiming for proper dietary habits in terms of both quantity and quality.

Sponsors

Istituto Auxologico Italiano
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of late-onset central hypogonadism: total T levels \< 8 nmol/L (or \< 12 nmol/L in the presence of calculated free T \< 225 pmol/L) combined with sexual symptoms (erectile dysfunction, low libido and loss of waking erections) \[12\]; * diagnosis of metabolic syndrome, defined as association of waist circumference (WC) \> 94 cm and at least two among the following criteria: triglycerides ≥ 150 mg/dl, HDL-C \< 40 mg/dl, glucose \> 100 mg/dl, blood pressure (BP) ≥ 130/85 mmHg \[33\]; * ability to give informed consent, in accordance with good clinical practice rules and applicable national laws.

Exclusion criteria

* History of hypothalamus-pituitary organic disorders and/or testicular diseases; * impossibility to assess cardiac autonomic regulation due to arrhythmias and/or current treatment for heart rate (HR) control (e.g., beta-blockers, antiarrhythmics); * impossibility to undergo clinical assessment; * impossibility or contraindications to perform exercise program (for instance, psychiatric disorders, severe musculoskeletal diseases, arrhythmias); * inability to give informed consent or unwillingness to be enrolled in the study.

Design outcomes

Primary

MeasureTime frameDescription
change in hypothalamic-pituitary-gonadal axis function6 monthsparticularly testosterone levels (nmol/l)

Secondary

MeasureTime frameDescription
Change in total cholesterol6 monthsChange in total cholesterol concentration (mg/dl)
Change in HDL cholesterol6 monthsChange in HDL cholesterol concentration (mg/dl)
Change in triglycerides6 monthsChange in triglycerides concentration (mg/dl)
Change in glucose profile6 monthsglycemia (mg/dl)
Change in kidney function6 monthscreatinine (mg/dl)
Change in aspartate aminotransferase6 monthsChange in aspartate aminotransferase concentration (U/L)
Change in alanine aminotransferase6 monthsChange in alanine aminotransferase concentration (U/L)
Change in C-reactive protein6 monthsChange in C-reactive protein concentration (mg/l)
Change in body composition6 monthspercentage of fat mass and free fat mass
Change in serum skeletal isoenzyme of alkaline phosphatase6 monthsChange in serum skeletal isoenzyme of alkaline phosphatase concentration (ug/l)
Change in erythrocyte sedimentation rate6 monthsChange in erythrocyte sedimentation rate (mm/h)
Change in cardiac autonomic regulation6 monthsAutonomic Nervous System Index (ANSI)
Change in nutrition quality6 monthsAmerican Heart Association (AHA) Diet Score
Change in perception of stress, fatigue, and somatic symptoms6 monthsshort version of 4SQ questionnaire considering 4 specific symptoms (total score ranging from 0 to 40)
Change in weekly physical activity volume6 monthsshort version of International Physical Activity Questionnaire, which focuses on intensity (nominally estimated in Metabolic Equivalents - MET - according to the type of activity) and duration (in minutes) of physical activity. The following levels will be considered: brisk walking (≈ 3.3 METs), other modalities of activity of moderate intensity (≈ 4.0 METs), and activities of vigorous intensity (≈ 8.0 METs).
Change in C-terminal telopeptide of type I collagen6 monthsChange in C-terminal telopeptide of type I collagen concentration (ng/l)

Countries

Italy

Contacts

Primary ContactLuca Giovanelli, MD
luca.giovanelli@unimi.it+3902619112808

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026